M&A · Healthcare · Pharmaceutical Preparations
XenoTherapeutics to acquire Repare Therapeutics Inc.
Announced Nov 14, 2025 · Closed Jan 28, 2026
Deal value$78MEV $5M
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationNot disclosed$1.82 per share
Transaction
- Acquirer
- XenoTherapeutics
- Target
- Repare Therapeutics Inc. (RPTX)
- Buyer type
- Strategic
- Offer price per share
- $1.82
- Enterprise value
- $5M
- Status
- Closed Jan 28, 2026
Deal protections
- Break fee (target pays)
- $2.0M · 2.6%
- Reverse fee (buyer pays)
- —
- Go-shop
- —
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Leerink Partners
Sector context · Healthcare
- Comparable deals
- 99 in the prior 24 months
- Premium
- Sector median 60.0%
- EV / Adj. EBITDA
- Sector median 14.5x
- Break fee
- 2.6% vs. 3.4% sector median
Timeline
- AnnouncedNov 14, 2025
- Proxy filedDec 3, 2025
- Definitive proxyDec 15, 2025
- Shareholder voteJan 16, 2026
- ClosedJan 28, 2026